JPM 2026 witnesses dealmaking optimism despite absence of mega M&As
The 44th Annual JP Morgan Healthcare Conference saw a focus on internal pipeline prioritization and bolt-on licensing agreements, with industry experts noting an absence of large biopharmaceutical mergers and acquisitions (M&A) announcements typically expected, says intelligence and productivity platform GlobalData.
Alison Labya, senior pharma business fundamentals Analyst at GlobalData, commented: “Lower interest rates and Trump-era deregulation drove momentum in large biopharmaceutical M&As in 2025, with reduced uncertainty around the impact of Trump’s tariff policies in H2 2025 further strengthening capital markets.”
Improving macroeconomic conditions sustained a positive sentiment for M&A activity in 2026 as GlobalData’s recent M&A Trends in Pharma – Q4 2025 report revealed a 59.3% uptick in total M&A deal value in Q4 2025 compared to the Q3 2025, totaling $80.2 billion. Furthermore, according to GlobalData’s recent Venture Capital Investment Trends In Pharma – Q4 2025 report showed a recovery in biotech venture financing with a 35% increase in total deal value in Q4 2025 to $5 billion compared to Q3 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze